Search the Newsreel

Price to sales forward of Agios Pharmaceuticals, Inc. – NASDAQ:AGIO

This article provides a brief financial overview for Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), specifically highlighting its price-to-sales forward metric. The content primarily comes from TradingView, indicating that the information is related to financial analysis and market data.

AGIOS PHARMACEUTICALS INC : CITIGROUP RAISES TARGET PRICE TO $52 FROM $46

Citigroup has increased its target price for Agios Pharmaceuticals Inc. to $52 from $46. This information was reported by Reuters on July 31, 2026. The article reiterates this new target price multiple times.

AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year

Agios Pharmaceuticals Inc (AGIO) Risk Assessment: Volatility, Financial Risk & Investment Risk

Agios Pharmaceuticals Inc (AGIO) has a risk assessment score of 3.24, placing it 149th out of 384 in the Biotechnology & Medical Research industry. The company's stock has a beta of 0.59, indicating it is less volatile than the S&P 500. This assessment provides …

Agios Pharmaceuticals Inc (AGIO) (Q2 2026) Earnings Call Highlights: Strong Mitapivat Revenue ...

This article first appeared on GuruFocus. Total Mitapivat Net Revenue: $44.7 million for Q2 2026, including $40.9 million in the US and $3.8 million outside the US. AQVESME Prescriptions: 442 cumulative prescriptions from REMS-certified physicians as of June 30, 2026, with 200 new prescriptions …

Agios Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Agios Pharmaceuticals Inc has reported its earnings results for the quarter that ended on June 30. The summary of these results is available through Reuters on TradingView. Readers can access the full article and unlimited news from various sources by using TradingView.

Agios Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AGIO) 2026-07-30

Agios Pharmaceuticals, Inc. published its Q2 2026 earnings call presentation, reporting an EPS of -$1.69, missing estimates by $0.02. However, the company's revenue of $44.75M exceeded expectations by $18.04M, showing a significant 259.25% year-over-year increase. The article highlights these key financial results from the …

Agios Pharmaceuticals Q2 Earnings Call Highlights

Agios Pharmaceuticals reported Q2 2026 mitapivat net revenue of $44.7 million, with a net loss of $100.7 million. The company is advancing its thalassemia launch and preparing for a potential sickle cell disease approval, maintaining approximately $1 billion in cash. Key growth drivers include …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

Pomerantz LLP is investigating potential securities fraud claims against Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) on behalf of its investors. This investigation follows a significant 6.74% drop in Agios's stock price after the company announced on July 21, 2026, that its Phase 2 trial for …

Agios Pharmaceuticals (NASDAQ: AGIO) lifts drug revenue but remains unprofitable

Agios Pharmaceuticals reported significantly increased rare-disease drug revenue, primarily from AQVESME and PYRUKYND, for the quarter and first half of 2026, though the company remains unprofitable. While product revenue rose sharply, the company still posted net losses due to substantial investments in R&D and …

Agios Pharmaceuticals Q2 Results: Revenue surges 259% YoY

Agios Pharmaceuticals reported a 259% year-over-year revenue increase in Q2 2026, reaching $44.7 million, primarily due to the successful U.S. launch of AQVESME for thalassemia. The company narrowed its net loss to $100.7 million and advanced its hematology pipeline, including securing FDA Priority Review …

Agios Pharmaceuticals Releases Q2 2026 Financial Results

Agios Pharmaceuticals beat Q2 2026 earnings estimates with a loss of $1.69 per share against an expected $1.70. The company reported $44.7M in revenue, a 259.3% increase year-over-year, largely due to strong sales of its thalassemia treatment, AQVESME. Wall Street maintains a positive outlook …

Agios Pharmaceuticals: Q2 Earnings Snapshot

Agios Pharmaceuticals Inc. (AGIO) reported a Q2 loss of $100.7 million, or $1.69 per share, which was better than analysts' expectations. The biopharmaceutical company also exceeded revenue forecasts, posting $44.7 million compared to an expected $22.7 million. Despite a 7% drop in the last …

Earnings Flash (AGIO) Agios Pharmaceuticals, Inc. Reports Q2 Revenue $44.7M, vs. FactSet Est of $26.4M

Agios Pharmaceuticals, Inc. (AGIO) reported Q2 revenue of $44.7 million, significantly surpassing FactSet's estimate of $26.4 million. The company also announced its Q2 2026 earnings call for July 30, 2026, and separately reported its Q2 2026 earnings results, with a narrower net loss per …

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Down on Disappointing Earnings

Agios Pharm earnings missed by $0.04, revenue topped estimates

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates

Adagio Medical Holdings Inc (ADGM) Institutional Confidence

This article details

Bronstein, Gewirtz & Grossman, LLC Encourages Agios Pharmaceuticals, Inc. (AGIO) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors in Agios Pharmaceuticals, Inc. (AGIO) following a significant stock price drop. This occurred after the company announced that its Phase 2 trial for tebapivat in sickle cell disease did not meet …

Tebapivat Sickle Cell Setback and Mitapivat Priority Review Could Be A Game Changer For Agios (AGIO)

In July 2026, Agios Pharmaceuticals reported topline Phase 2 results for tebapivat in sickle cell disease, showing hemoglobin and hemolysis improvements but insufficient differentiation versus placebo, and consequently decided to discontinue tebapivat's development for this use. At the same time, Agios highlighted that the …

Agios Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $43.12, Implies 23% Upside

Agios Pharmaceuticals, Inc. (AGIO) has seen its average 12-month price target increased to $43.12 from $42.75 by 8 analysts, implying a 23% potential upside from its July 29 closing price. The consensus rating for AGIO remains a "Buy" from 10 analysts, with 7 "Buy" …

Law firm investigates Agios Pharmaceuticals over possible securities fraud after trial failure news.

Pomerantz LLP is investigating Agios Pharmaceuticals and its executives for potential securities fraud. This follows the company's announcement that its Phase 2 trial for the drug tebapivat failed to meet expectations, leading to the halting of further drug development and a 6.74% drop in …

Sio Capital trims Adagio Medical (ADGM) holding to 3.15% under 5% threshold

Sio Capital Management, LLC has reported a decrease in its beneficial ownership of Adagio Medical Holdings, Inc. (ADGM) common stock to 3.15%, or 698,989 shares, as of June 30, 2026. This position is below the 5% threshold for passive investment disclosure, with Sio Capital …

Understanding the Setup: (AGIO) and Scalable Risk

This article analyzes Agios Pharmaceuticals Inc. (AGIO), highlighting weak sentiment across all horizons supporting a short bias. It identifies a mid-channel oscillation pattern and presents an exceptional 65.6:1 risk-reward short setup. The analysis includes AI-generated trading strategies for different risk profiles and a multi-timeframe …

Imagion Biosystems Ltd. Revenue Breakdown – ASX:IBX

Agios Pharmaceuticals (AGIO) Is Down 7.7% After Halting Tebapivat While Advancing Mitapivat in Sickle Cell Disease – Has The Bull Case Changed?

Agios Pharmaceuticals experienced a 7.7% stock drop after halting the development of tebapivat for sickle cell disease, citing insufficient differentiation. Simultaneously, the company is advancing mitapivat through an FDA Priority Review for the same condition, with a PDUFA decision set for November 1, 2026. …

Adagio Medical Holdings Inc

This article provides an overview of Adagio Medical Holdings Inc (ADGM), including its current stock price and market capitalization. It highlights that revenue breakdown data by business and region has not yet been disclosed by the company. The page also mentions Finsights' role in …

Adagio Medical Holdings Inc (ADGM) Cash Flow

This article provides a detailed cash flow statement for Adagio Medical Holdings Inc (ADGM), covering quarterly data for operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flow and ADGM's performance in these areas, such as its …

Adagio Medical Holdings Inc (ADGM) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Adagio Medical Holdings Inc (ADGM) focusing on its dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts. The page also presents current …

Agios Pharmaceuticals Inc (AGIO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Agios Pharmaceuticals Inc (AGIO) dividends and stock splits, noting that no dividends have been distributed over the past five years. It presents current stock performance data, including market cap and P/E ratio, and offers an analysis of the …

Agios Pharmaceuticals Inc (AGIO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Agios Pharmaceuticals Inc (AGIO), noting its current valuation score of 8.40 and a rank of 125 out of 385 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -4.96, which is …

Agios Pharmaceuticals Inc (AGIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Agios Pharmaceuticals Inc (AGIO), detailing its price momentum, support and resistance levels, and indicator-based signals. It highlights that AGIO's current price momentum score is 4.07, ranking 279 out of 386 in its industry, trading between a resistance …

Agios Pharmaceuticals (AGIO) Could Be 11% Undervalued Following Mixed Sickle Cell Updates

Agios Pharmaceuticals (AGIO) shares are reacting to mixed sickle cell disease updates, leading to an 8.21% drop in the last 7 days, despite a 48.83% gain over 90 days. The company ended development of tebapivat for sickle cell but secured FDA Priority Review for …

AGIO|Agios Pharmaceuticals Inc|Price:36.360|Chg%:+0.080

This article provides a detailed financial summary for Agios Pharmaceuticals Inc. (AGIO), including its latest stock price, market cap, and key financial statements such as income statement, balance sheet, and cash flow statement. It highlights the company's earnings date, EPS and revenue forecasts, and …

Adagio Medical Holdings, Inc Revenue Breakdown – NASDAQ:ADGM

The article provides a revenue breakdown for Adagio Medical Holdings, Inc (NASDAQ: ADGM) based on data from TradingView. It offers an overview of the company's financials, including statements, statistics, dividends, earnings, and segment performance. The content is primarily a data placeholder and navigational information …

Agios Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AGIO

Agios Pharmaceuticals, Inc. reported a total revenue of $54.03 million USD last year. The primary source of this revenue was its "Medicines for Cellular Metabolism" segment, contributing the entire $54.03 million USD, an increase from $36.50 million USD in the prior year. Geographically, the …